Emily R. Greene

Closest collaborators

The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Chrystal M Paulos · 2 shared papers, 2026 · strength 0.47
   • Paper A phase Ib/II trial of XL888 (HSP90 inhibitor) and pembrolizumab in metastatic pancreatic cancer with translational imm… DOI 10.1016/j.canlet.2025.218233↗
   • Paper High-Dimensional Protein Analysis Uncovers Distinct Immunologic and Stromal Features in Primary and Metastatic Pancreat… DOI 10.1158/0008-5472.can-25-1697↗
2. Cameron J. Herting · 2 shared papers, 2026 · strength 0.47
   • Paper A phase Ib/II trial of XL888 (HSP90 inhibitor) and pembrolizumab in metastatic pancreatic cancer with translational imm… DOI 10.1016/j.canlet.2025.218233↗
   • Paper High-Dimensional Protein Analysis Uncovers Distinct Immunologic and Stromal Features in Primary and Metastatic Pancreat… DOI 10.1158/0008-5472.can-25-1697↗
3. Natalie K. Horvat · 2 shared papers, 2026 · strength 0.47
   • Paper A phase Ib/II trial of XL888 (HSP90 inhibitor) and pembrolizumab in metastatic pancreatic cancer with translational imm… DOI 10.1016/j.canlet.2025.218233↗
   • Paper High-Dimensional Protein Analysis Uncovers Distinct Immunologic and Stromal Features in Primary and Metastatic Pancreat… DOI 10.1158/0008-5472.can-25-1697↗
4. Olatunji Boladale Alese · 2 shared papers, 2026 · strength 0.47
   • Paper A phase Ib/II trial of XL888 (HSP90 inhibitor) and pembrolizumab in metastatic pancreatic cancer with translational imm… DOI 10.1016/j.canlet.2025.218233↗
   • Paper High-Dimensional Protein Analysis Uncovers Distinct Immunologic and Stromal Features in Primary and Metastatic Pancreat… DOI 10.1158/0008-5472.can-25-1697↗
5. Gregory B. Lesinski · 2 shared papers, 2026 · strength 0.47
   • Paper A phase Ib/II trial of XL888 (HSP90 inhibitor) and pembrolizumab in metastatic pancreatic cancer with translational imm… DOI 10.1016/j.canlet.2025.218233↗
   • Paper High-Dimensional Protein Analysis Uncovers Distinct Immunologic and Stromal Features in Primary and Metastatic Pancreat… DOI 10.1158/0008-5472.can-25-1697↗
6. Maria Diab · 2 shared papers, 2026 · strength 0.47
   • Paper A phase Ib/II trial of XL888 (HSP90 inhibitor) and pembrolizumab in metastatic pancreatic cancer with translational imm… DOI 10.1016/j.canlet.2025.218233↗
   • Paper High-Dimensional Protein Analysis Uncovers Distinct Immunologic and Stromal Features in Primary and Metastatic Pancreat… DOI 10.1158/0008-5472.can-25-1697↗
7. Bassel F. El‐Rayes · 2 shared papers, 2026 · strength 0.47
   • Paper A phase Ib/II trial of XL888 (HSP90 inhibitor) and pembrolizumab in metastatic pancreatic cancer with translational imm… DOI 10.1016/j.canlet.2025.218233↗
   • Paper High-Dimensional Protein Analysis Uncovers Distinct Immunologic and Stromal Features in Primary and Metastatic Pancreat… DOI 10.1158/0008-5472.can-25-1697↗
8. Olumide B. Gbolahan · 1 shared paper, 2026 · strength 0.24
   • Paper A phase Ib/II trial of XL888 (HSP90 inhibitor) and pembrolizumab in metastatic pancreatic cancer with translational imm… DOI 10.1016/j.canlet.2025.218233↗
9. Juan Manuel Sarmiento · 1 shared paper, 2026 · strength 0.23
   • Paper High-Dimensional Protein Analysis Uncovers Distinct Immunologic and Stromal Features in Primary and Metastatic Pancreat… DOI 10.1158/0008-5472.can-25-1697↗
10. Alyssa M. Krasinskas · 1 shared paper, 2026 · strength 0.23
    • Paper High-Dimensional Protein Analysis Uncovers Distinct Immunologic and Stromal Features in Primary and Metastatic Pancreat… DOI 10.1158/0008-5472.can-25-1697↗
11. Mihir Maheshkumar Shah · 1 shared paper, 2026 · strength 0.23
    • Paper High-Dimensional Protein Analysis Uncovers Distinct Immunologic and Stromal Features in Primary and Metastatic Pancreat… DOI 10.1158/0008-5472.can-25-1697↗
12. Shishir Kumar Maithel · 1 shared paper, 2026 · strength 0.23
    • Paper High-Dimensional Protein Analysis Uncovers Distinct Immunologic and Stromal Features in Primary and Metastatic Pancreat… DOI 10.1158/0008-5472.can-25-1697↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.